CoChat

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide

Open access
Basalay, Maryna V., Davidson, Sean M., Yellon, Derek M. · 2019 · Cardiovascular Drugs and Therapy

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Purpose: A substantial number of ischaemic stroke patients who receive reperfusion therapy in the acute phase do not ever fully recover. This reveals the urgent need to develop new adjunctive neuroprotective treatment strategies alongside reperfusion therapy. Previous experimental studies demonstrated the potential of glucagon-like peptide-1 (GLP-1) to reduce acute ischaemic damage in the brain. Here, we examined the neuroprotective effects of two GLP-1 analogues, liraglutide and semaglutide. Methods: A non-diabetic rat model of acute ischaemic stroke involved 90, 120 or 180 min of middle cerebral artery occlusion (MCAO). Liraglutide or semaglutide was administered either i.v. at the onset of reperfusion or s.c. 5 min before the onset of reperfusion. Infarct size and functional status were evaluated after 24 h or 72 h of reperfusion. Results: Liraglutide, administered as a bolus at the onset of reperfusion, reduced infarct size by up to 90% and improved neuroscore at 24 h in a dose-dependent manner, following 90-min, but not 120-min or 180-min ischaemia. Semaglutide and liraglutide administered s.c. reduced infarct size by 63% and 48%, respectively, and improved neuroscore at 72 h following 90-min MCAO. Neuroprotection by semaglutide was abolished by GLP1-R antagonist exendin(9-39). Conclusion: Infarct-limiting and functional neuroprotective effects of liraglutide are dose-dependent. Neuroprotection by semaglutide is at least as strong as by liraglutide and is mediated by GLP-1Rs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10557-019-06915-8

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Neuroprotection induced by liraglutide administration in the acute ischaemic stroke model is dose-dependent. Rats were subjected to 90-min MCAO, followed by 24-h reperfusion. Vehicle or liraglutide was administered as i.v. bolus at the onset of reperfusion. Hemispheric lesion volumes corrected for oedema (%HLVe) (a) and neuroscores (b) were evaluated at the end of reperfusion period. *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 1 Neuroprotection induced by liraglutide administration in the acute ischaemic stroke model is dose-dependent. Rats were subjected to 90-min MCAO, followed by 24-h reperfusion. Vehicle or liraglutide was administered as i.v. bolus at the onset of reperfusion. Hemispheric lesion volumes corrected for oedema (%HLVe) (a) and neuroscores (b) were evaluated at the end of reperfusion period. *P < 0.05; **P < 0.01; ***P < 0.001CC BY · PubMed Central
Fig. 2 Reperfusion delay is a limiting factor for neuroprotection by liraglutide. Rats were subjected to 90-, 120- or 180-min MCAO, followed by 24-h reperfusion. Liraglutide was administered as i.v. bolus at the onset of reperfusion. Hemispheric lesion volumes corrected for oedema (%HLVe) (a) and neuroscores (b) were evaluated at the end of reperfusion period. Individual data and median with interquartile range are shown for each group. *P < 0.05; ***P < 0.001
Fig. 2 Reperfusion delay is a limiting factor for neuroprotection by liraglutide. Rats were subjected to 90-, 120- or 180-min MCAO, followed by 24-h reperfusion. Liraglutide was administered as i.v. bolus at the onset of reperfusion. Hemispheric lesion volumes corrected for oedema (%HLVe) (a) and neuroscores (b) were evaluated at the end of reperfusion period. Individual data and median with interquartile range are shown for each group. *P < 0.05; ***P < 0.001CC BY · PubMed Central
Fig. 3 Neuroprotection by semaglutide is at least as strong as by liraglutide and is mediated by GLP-1Rs. Rats were subjected to 90-min MCAO, followed by 72-h reperfusion. Liraglutide (Lir.) or semaglutide (Sem.) was administered s.c. 5 min before the onset of reperfusion. Hemispheric lesion volumes corrected for oedema (%HLVe) (a) and neuroscores (b) were evaluated at the end of reperfusion period. Individual data and median with interquartile range are shown for each group. The numbers of the animals who did not survive 72-h reperfusion or had to be euthanised due to having reached the humane endpoints are presented in the boxes. *P < 0.05; **P < 0.01; ***P < 0.001
Fig. 3 Neuroprotection by semaglutide is at least as strong as by liraglutide and is mediated by GLP-1Rs. Rats were subjected to 90-min MCAO, followed by 72-h reperfusion. Liraglutide (Lir.) or semaglutide (Sem.) was administered s.c. 5 min before the onset of reperfusion. Hemispheric lesion volumes corrected for oedema (%HLVe) (a) and neuroscores (b) were evaluated at the end of reperfusion period. Individual data and median with interquartile range are shown for each group. The numbers of the animals who did not survive 72-h reperfusion or had to be euthanised due to having reached the humane endpoints are presented in the boxes. *P < 0.05; **P < 0.01; ***P < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 68

Metadata

Authors
Basalay, M. V., Davidson, S. M., & Yellon, D. M.
Affiliations
University College London (GB)
Corresponding author
Yellon, Derek M.
Venue
Cardiovascular Drugs and Therapy
Published
2019-11-13
Volume
33
Issue
6
Pages
661-667
ISSN
  • 0920-3206 (ISSN-L)
  • 1573-7241
OpenAlex
W2984187781
Cited by
68
References
41
Citations by year
2026: 8 · 2025: 16 · 2024: 11 · 2023: 6 · 2022: 10 · 2021: 10 · 2020: 6
FWCI
2.86
Type
journal article
Language
en
Open access
Licence
Locations
  • Cardiovascular Drugs and Therapy (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • The Hatter Foundation (2019)
  • The Rubin Charitable Trust (2019)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
neuroprotection, ischemic stroke, ischemia-reperfusion injury, GLP-1 analogues, liraglutide, semaglutide, GLP-1 receptor, middle cerebral artery occlusion, infarct size, functional recovery, exendin-9-39, GLP-1 receptor antagonists
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Glucagon-Like Peptides, Male, Time Factors, Reperfusion, Reperfusion Injury, Rats, Sprague-Dawley, Neuroprotective Agents, Infarction, Middle Cerebral Artery, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide. https://app.cochat.ai/papers/10.1007/s10557-019-06915-8
The paper
Basalay, M. V., Davidson, S. M., & Yellon, D. M. (2019). Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-019-06915-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.